Transforming cancer treatment with
Protein Phosphatase 2A inhibitors
Unveiling the first of a novel class of therapeutic agents
Lixte Biotechnology (NASDAQ:LIXT) holds the world’s only clinical-stage PP2A inhibitor, with multiple Phase 1b/2 trial results on the horizon and protected by long-term patents
Dear Undervalued Pharma Seekers,
Readers who took quick action on stocks that I recently covered, could have locked in profits from 70%, and counting, to 900%, but when promising Biopharmaceutical companies work, the returns often dwarf that.
LIXTE is positioned to deliver a potential once in a lifetime Cancer protocol platform win for patients and investors. My research and the charts tell me smart investors should buy (NASDAQ:LIXT) up to at least the $8-10 range, soaking up the low hanging shares and let it play out. If LIXTE’s lead compound, LB-100, hits on just one of the 3 ongoing trials, the results could literally be life changing.
Make no mistake, I only cover companies that I believe you, and other readers, have a great chance to get in before the trading masses, algos, and institutions are able to send shares soaring on expected upcoming news announcements.
These small caps move quick, so, if you wait to learn about (LIXT) when news breaks, you’ll miss a big part of the move.
The catalysts are coming soon, so I’m sharing some of the information you need to get ahead of them. The float is under 5 million shares, which means that the stock will likely move quickly on any positive news from the 3 upcoming clinical trial results.
So, taking a position anywhere below the $10 mark should allow investors to sell into the teens on positive cancer trial updates.
This probability-weighted valuation model highlights the asymmetric upside of LIXTE’s LB-100. Using conservative assumptions and indication-level success probabilities:
The Bayesian Valuation Snapshot is built by modeling LB-100’s three ongoing trials; ovarian, MSS colorectal, and soft tissue sarcoma across low, mid, and high success scenarios.
Each scenario assumes different clinical success probabilities, comparable oncology licensing revenue potential, and standard biotech economics, like royalty-equivalent values and risk discounting.
In the low case, only one trial succeeds, producing $19.65/share. The mid case assumes two succeed, at $69.88/share, and the high case all three succeed, reaching $177.45/share.
By weighting these outcomes with industry-standard Phase 2 oncology success probabilities and adjusting for timelines and risk, the model produces a probability-weighted valuation of $143/share about 30× above today’s price. In short, this framework captures both the risk of trial failure and the asymmetric upside if even one indication hits, showing why LB-100 represents such a powerful risk/reward setup.
This is why Recent cancer news set (NASDAQ:LIXT) Soaring from .30 to a high of more than $5.
LB-100 recently cleared its first safety hurdle, with a favorable toxicity profile, and LIXT is now advancing three active Phase 1b/2 trials for LB-100 in combination with established cancer therapies, each partnered with leading organizations.
In ovarian clear-cell carcinoma, LB-100 is being tested with GlaxoSmithKline or GSK’s checkpoint inhibitor dostarlimab at MD Anderson and Northwestern University, with interim data expected in Q4 2025.
At the Netherlands Cancer Institute, LB-100 is in a trial with Roche’s PD-L1 therapy atezolizumab for MSS colorectal cancer, a patient group that typically does not respond to immunotherapy.
In soft-tissue sarcoma, LIXT is working with the Spanish Sarcoma Group (GEIS) to combine LB-100 with doxorubicin, with Phase 1b results also anticipated later this year.
With multiple Phase 1b/2 trial results on the horizon, Lixte’s (LIXT) collaborations are set to deliver multiple clinical updates in the coming months and offer compelling catalysts.
In addition to these trials, the Inland Cancer Institute published groundbreaking data in AACR’s Cancer Discovery showing LB-100 causes “lethal activation”; overdriving colon cancer cells until they collapse in cell death. This is a powerful new therapeutic strategy and Lixte is ahead of everyone else in applying it clinically.
Nature Reviews validated this breakthrough in its “Too Much of a Good Thing” editorial.
Understanding MSS Colorectal Cancer vs. Colon Cancer
Colorectal cancer (CRC) is a broad category of cancers beginning in the colon or rectum. About 85% are microsatellite stable (MSS), meaning they do not respond well to immunotherapies; these are the hardest-to-treat cases. LIXTE Biotechnology’s (LIXT) Roche trial targets exactly this MSS subgroup. The Cancer Discovery publication, however, shows that LB-100’s mechanism may have utility across colon cancer more broadly, not just the MSS subtype.
GSK plc (NYSE: GSK) and Roche Holding AG (OTCQX: RHHBY) aren’t just partners, they’re two of the largest cancer drug companies in the world, with multi-billion-dollar oncology portfolios and global market leadership.
Yes, the biggest Global oncology names are now testing their flagship drugs with LB-100 in combination trials. That’s a powerful signal that that this small cap biotech (LIXT) is on the radar of the industry’s biggest players. With multiple collaborations underway, the upcoming news cycle should be nothing short of legendary.
Without a doubt, LXTE is an explosive biopharma play, with a strong risk reward proposition that could mean losing all the chips on the table. However, some of the planet’s smartest money in this space, Roche and GSK, are funding the trials and they’re in the business to win. In fact, it’s not a stretch to think that both of these companies are looking at LIXT as an acquisition target.
LIXTE’s President is a Biotechnology Executive who not only oversaw numerous clinical trials from start to publication, he co-founded a company that was acquired by a leading Nasdaq genomics company and then helped lead another company to partner with this same $15+ billion leader in a pact to sell diagnostic tests to its clients, so he obviously knows how to structure deals.
Of course, $15 billion is tiny compared to Roche and GSK, but even on the bigger deals the fundamentals are the key to success.
LB‑100 has been under scientific evaluation for nearly a decade, with its first human safety and tolerability study published in Clinical Cancer Research in 2017, marking the beginning of its translation from bench to bedside. Since then, research into LB‑100 has grown significantly: the compound’s mechanism and preclinical efficacy are detailed in over 25 peer-reviewed publications, spanning studies on chemotherapy synergy, immunotherapy enhancement, glioblastoma models, and neoantigen generation (LIXTE).
Unlike a single-use drug, LB-100 has the potential to function as a platform technology, enhancing the power of existing therapies while allowing for lower, less toxic doses. That combination could keep more patients on treatment longer, addressing the reality that up to 59% of cancer patients discontinue therapy due to side effects. With patents extending into the 2040s, partnerships with global leaders like GSK and Roche, and applicability across multiple cancer types, LB-100 is positioned not just to change treatment protocols, but to impact millions of lives worldwide, while opening the door to multi-billion-dollar licensing and royalty streams in a projected $530-billion oncology market.
LIXT’s chart shows it’s consolidating; with major support over $3 & less than 5M shares in the float, this is set up for a space launch.
The Most Asymmetric Trade in Cancer Right Now: (NASDAQ:LIXT)
First-in-class.
No competition.
Huge partners.
And still under $5.
Lixte Biotechnology quietly holds the only clinical-stage PP2A inhibitor in the world, LB-100, a potential a cancer power-up that supercharges existing cancer therapies to find hidden tumors, reduce toxicity, and enhance immune response.
LB-100 is a first-in-class molecule that disables cancer’s repair system and lights up tumors to the immune system.
When LB-100 is active tumors can’t fix themselves, the immune system finally sees the cancer, and other treatments become more effective; at better doses, which translates into fewer side effects, fewer dropouts, and more survivors.
The bottom line is this: everything you’ve just read points to LB-100’s efficacy and mechanisms are supported by 25+ publications, major academic centers, and Global leaders like MD Anderson, NKI, Northwestern, City of Hope, multiple imminent trial readouts, and a market valuation that doesn’t yet reflect its potential. There’s far more to uncover, so don’t stop here. Go to LIXTE’s website, read their press releases, watch their videos, and dig into independent due diligence. When you see the science, the partnerships, and the timing lined up the way they are now, I believe you’ll see exactly what I see; a rare, high conviction opportunity that may not come around again.
We’ve had a strong run of winners this past year and LIXT has all the hallmarks of another one.
That said, biotech is a high-volatility sector and even the most promising stories can hit unexpected setbacks, so set limits, monitor company news closely, and manage risk by limiting your exposure to what you can afford. However, as you know, setups like this don’t come often. LIXTE owns a first-in-class, IP-protected molecule, partnered with heavyweight partners, including two of the biggest names in oncology, and is heading into multiple near-term catalysts; all while trading at a valuation that barely reflects their last funding round.
Good Luck,
Editor
DISCLOSURE: WallStreet-PR.com (WSTPR), owns and operates wallstreet-pr.com is a third-party publisher and news release service provider which disseminates corporate news electronically through multiple online media platforms. WSTPR is NOT an affiliate with any of the companies mentioned in our reports. WSTPR is a news distribution service and is not registered with FINRA or any other professional licensing service. WSTPR is not an analyst, broker dealer or advisor, and holds no such licenses. WSTPR may NOT offer to buy, sell, or hold any security. WSTPR corporate profiles will NEVER be a solicitation or recommendation of any kind, of any security mentioned. The materials in all our releases are intended to be for informational purposes only and should never be considered research or due diligence on any company mentioned. All readers are encouraged to perform standard due diligence by reading the company’s filings at SEC.gov. Readers should consult their broker or licensed professional before investing in any company. All materials in this release are based on publicly available statements made by the companies. WSTPR is not liable for any investment decisions made by any readers or subscribers. Any investment could result in you losing all your money from investing in any stock. WSTPR’s editor owns no shares of SYTA restricted shares of Kraig Labs no shares of Venu holdings and no shares of any of the other mentioned companies. The editors of WSTPR can trade in these stocks at any time on news or technical analysis indicators and will not update with position size, entry’s or exits. Trade any of these stocks at your own risk. You should know this is a conflict of interest. Publisher charges $1,000 per editorial press release on WSTPR, and is contracted by Micro Cap Advisory for editorial coverage, and traffic to this web site for Siyata Mobil Inc. and Venu Holdings and could spend up to twenty thousand dollars a week each on investor awareness. WSTPR’s editors have also been contracted to write editorials about Kraig Labs by KAROLUS, who is contracted directly with the company and owns restricted non tradable shares and receives cash compensation for the distribution of this report. WSTPR will also be using financial marketing tools and platform to enhance distribution of this report. WSTPR and its editors own no shares of any other stocks in this editorial and will not be trading in PLANTIR, APPLOVIN, SIYATA or KRAIG unless disclosed herein. Editors are paid to put a best-case scenario profile out to the investing public. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSTPR undertakes no obligation to update such statements. WallStreetPR.com is a news and opinion website operating under the protections of the First Amendment to the United States Constitution. The content on this site represents the views and opinions of its authors and is intended for informational purposes only. Any sponsored content will be clearly disclosed, and all readers are encouraged to perform their own due diligence before making investment decisions. WallStreetPR does not offer investment advice or securities recommendations.
